GlassScriptPhysician profile
George I Lin
NPI 1679676035
$28,799.41
in general payments reported to CMS, 2019-2025
41 companies · $4,156 in 2025
The $4,156 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,130 · 2020: $2,245 · 2021: $3,713 · 2022: $3,575 · 2023: $4,136 · 2024: $3,845 · 2025: $4,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,116.48 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,043.03 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $4,904.00 | 2019-2025 | Vemlidy |
| Amgen INC. | $3,001.22 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $2,560.21 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $2,042.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,942.93 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $1,626.54 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,367.87 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $658.74 | 2022 | |
| Dexcom, INC. | $571.09 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Pfizer INC. | $568.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $566.69 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $402.78 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $391.42 | 2021-2025 | Austedo Xr |
| Abbvie INC. | $336.38 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.